Cancer-associated fibroblasts, or CAFs, are not cancer cells themselves. They are recruited and reprogrammed neighbors that form a critical part of the tumor microenvironment, the complex ecosystem of cells, vessels, and scaffold material that surrounds every tumor. In papillary thyroid carcinoma, the most common form of thyroid cancer, high CAFs expression has been linked to extrathyroidal extension, cervical lymph node metastasis, and multifocal disease. In other words, tumors rich in activated fibroblasts tend to behave badly, even though papillary thyroid carcinoma as a whole carries a relatively favorable prognosis. The clinical dilemma is that this biological information has traditionally been locked inside the tumor, accessible only after surgery, when pathologists stain tissue sections for fibroblast markers under a microscope.

The Chinese team, led by Tingting Li of the Department of Ultrasound, set out to break that barrier. Their reasoning rested on a physical principle: activated fibroblasts are prolific builders. They secrete extracellular matrix components such as collagen and release matrix-modifying enzymes that cross-link and remodel the tumor stroma. The result is a tumor that is not just biologically aggressive but mechanically stiffer. If stiffness could be measured quantitatively, it might serve as a non-invasive proxy for fibroblast activation. Shear wave elastography, available on modern ultrasound systems, does exactly that, generating maps of tissue stiffness expressed in kilopascals by tracking how shear waves propagate through tissue.

Between December 2023 and December 2024, the researchers enrolled consecutive patients who underwent thyroid surgery at their hospital. Each participant received conventional ultrasound and shear wave elastography within one month of surgery, using an Aixplorer system with a high-frequency linear probe. A single sonographer with more than a decade of thyroid experience acquired all images, and two blinded sonographers independently evaluated every parameter, with disagreements settled by a third. Conventional features recorded included tumor size, echogenicity, margins, aspect ratio, punctate echogenic foci, suspected extrathyroidal extension, and blood flow graded on the Adler scale from 0 for no flow to 3 for rich flow. Elastography yielded maximum, mean, minimum, and standard deviation elasticity values, averaged over at least three acquisitions per lesion.

The ground truth came from the operating room and the pathology laboratory. After tumor removal, tissue was fixed, embedded, and sectioned at four micrometers, then stained immunohistochemically for two canonical CAFs markers: fibroblast activation protein, or FAP, and alpha-smooth muscle actin, or alpha-SMA. A blinded pathologist scored staining intensity and the proportion of positive stromal cells across five high-magnification fields, multiplying the two scores into an immunoreactivity score, or IRS. Cases were split into low and high expression groups at an IRS cutoff of six, the median value. Reproducibility was excellent, with intra-class correlation coefficients of 0.934 for FAP and 0.939 for alpha-SMA.

The results were striking. Tumors in the high-expression groups were larger, more often suspected of extending beyond the thyroid capsule, and dramatically stiffer. Mean Emax was 50.60 kilopascals in the low FAP group versus 97.01 kilopascals in the high FAP group, with a nearly identical split for alpha-SMA. Elasticity heterogeneity, captured by the standard deviation ESD, also differed sharply between groups. Blood flow grade separated the FAP groups but not the alpha-SMA groups. Notably, the familiar grayscale features that radiologists rely on daily, including echogenicity, margins, aspect ratio, and punctate echogenic foci, showed no significant association with fibroblast expression at all.

Correlation analysis sharpened the picture. The immunoreactivity scores of both markers correlated most strongly with Emax, with Spearman coefficients of 0.555 for FAP and 0.575 for alpha-SMA, both highly significant. Multivariate logistic regression then distilled the independent predictors. For high FAP expression, blood flow grade 2 to 3 roughly doubled the odds, with an odds ratio of 2.513, while each unit increase in Emax raised the odds modestly but significantly. For high alpha-SMA expression, only Emax survived as an independent factor. Receiver operating characteristic analysis gave Emax an area under the curve of 0.799 for FAP and 0.819 for alpha-SMA, performance the authors characterize as good. Adding blood flow grade nudged the FAP area to 0.826, an improvement that fell short of statistical significance.

Why would the stiffest point of a tumor carry more biological information than its appearance in grayscale? The authors propose a mechanistic chain: activated fibroblasts flood the tumor with collagen and remodel the extracellular matrix, raising tissue stiffness, which elastography detects as elevated elasticity values. They are careful to note that this remains a hypothesis, since the study is observational and cannot establish causality. The divergence between the two markers is equally intriguing. Blood flow predicted FAP expression but not alpha-SMA expression, hinting that FAP-positive fibroblasts may be more tightly entwined with tumor angiogenesis than their alpha-SMA-positive counterparts, a reflection of the growing recognition that CAFs are a heterogeneous family of cells with distinct origins and functions.

The clinical implications could be substantial. If a preoperative Emax value flags a fibroblast-rich tumor, surgeons might scrutinize the operative field more vigilantly for capsular invasion and tailor the extent of resection accordingly, easing the chronic tension between under-treatment and over-treatment in papillary thyroid carcinoma. CAFs themselves are increasingly pursued as therapeutic targets, and a non-invasive readout of their activation could eventually help select patients for such therapies. The authors also suggest that combining elastography with serum fibroblast growth factor 21, a hormone recently linked to thyroid cancer aggressiveness, may enable richer risk stratification.

The study has limits the authors acknowledge candidly. It was a single-center retrospective analysis without an a priori sample size calculation, Doppler grading is inherently subjective, no clinical outcome data were available, and two markers cannot capture the full diversity of cancer-associated fibroblasts. Larger, prospective, multi-center cohorts with external validation will be needed before Emax enters routine decision-making. Still, the core message is hard to ignore: a number that takes seconds to acquire on an ordinary ultrasound machine may quietly report on the hidden cellular workforce that makes a thyroid tumor dangerous, turning a picture of anatomy into a glimpse of biology.

Subject of Research: Using shear wave elastography to non-invasively detect cancer-associated fibroblast expression in papillary thyroid carcinoma

Article Title: Ultrasound features for identifying cancer-associated fibroblasts expression in papillary thyroid carcinoma

Article References: Li, T., Xue, J., Li, X., Hao, C., & Zhao, Z. (2026). Ultrasound features for identifying cancer-associated fibroblasts expression in papillary thyroid carcinoma. Frontiers in Endocrinology, 17, Article 1914939. https://doi.org/10.3389/fendo.2026.1914939

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1914939

Keywords: papillary thyroid carcinoma, cancer-associated fibroblasts, shear wave elastography, ultrasound, tumor microenvironment, Emax, FAP, alpha-SMA, tumor stiffness, extracellular matrix, biomarkers, preoperative assessment

Dilated cardiomyopathy, or DCM, is characterized by enlargement and weakening of the ventricles, and cardiac fibrosis — the excessive accumulation of extracellular matrix proteins such as collagens — is a major driver of that adverse remodeling. Fibrosis stiffens the heart wall, impairs its ability to fill with blood, and progressively worsens function. But fibrosis is not produced by a single, uniform population of cells. Cardiac fibroblasts occupy dynamic, injury-dependent transcriptional states, and single-cell and single-nucleus profiling has revealed marked stromal heterogeneity in both healthy and diseased myocardium. Activated fibroblasts can be sparse in non-failing hearts yet enriched in cardiomyopathy, and previous work has implicated the transcription factor MEOX1 as a regulator of fibroblast activation. What remained uncertain was which human DCM fibroblast state is most reproducibly enriched across cohorts, and whether its disease association is stronger than that of the conventional ACTA2-high myofibroblast state that has dominated the literature.

To answer that question, the study used a prespecified discovery-and-validation design built entirely on publicly available data. The discovery cohort, GSE183852, contained left-ventricular nuclei from 25 non-failing donor hearts and 13 DCM hearts. The external validation cohort, SCP1303, contained 16 normal and 11 DCM hearts, with hypertrophic cardiomyopathy samples excluded from the primary comparison. Fibroblasts from the discovery cohort — 49,124 nuclei in total — were independently reclustered in Seurat using log normalization, 2,500 variable features, 30 principal components, a shared-nearest-neighbor graph, and Louvain clustering at resolution 0.5, with a fixed random seed to ensure reproducibility. Critically, the author treated the donor, not the individual nucleus, as the statistical unit of inference, a decision that guards against the false discoveries that arise when thousands of nuclei from one patient are mistakenly counted as independent biological replicates.

The reclustering resolved multiple fibroblast states and revealed substantial compositional variation between donors. One cluster stood out: cluster two showed high expression of MEOX1 and FAP together with relatively low ACTA2, the gene encoding alpha-smooth muscle actin that marks the classical contractile myofibroblast. The study is careful to note that ACTA2-low is a relative property — ACTA2 was detected in 14.7 percent of cluster-two nuclei versus 57.3 percent in the discrete ACTA2-high cluster 16 — and does not imply absent expression or a lack of overall ACTA2 induction in disease. Cluster two nonetheless retained clear extracellular-matrix features, expressing FN1, POSTN, COL1A1 and COL3A1, and an unbiased marker analysis surfaced RFX2, CYR61, FOS, EGR1, DDAH1, CTGF, FAP and MEOX1 among its leading genes. The state was therefore defined by the combined three-marker pattern rather than any single gene.

The quantitative case for disease enrichment rests on donor-level proportions. Cluster two made up a median 5.81 percent of fibroblasts in DCM hearts versus 0.28 percent in donor hearts, a difference that was highly significant after false-discovery-rate correction. The mean DCM-minus-donor difference was 0.165, with a 95 percent confidence interval of 0.035 to 0.349 derived from 10,000 iterations of donor bootstrap resampling. Perhaps most tellingly, sequentially omitting each of the 38 donors one at a time never flipped the direction of the effect, which stayed within a range of 0.102 to 0.179. Sensitivity analyses across clustering resolutions showed that while the default state merged into broader compartments at lower resolutions, higher-resolution counterparts retained disease enrichment with p-values below 2 × 10⁻⁶. By contrast, the ACTA2-high cluster 16 showed only a smaller, non-significant abundance difference between groups.

Covariate modeling added nuance rather than contradiction. Heteroscedasticity-consistent HC3 linear models estimated a DCM coefficient of 0.165 unadjusted, 0.166 after adjusting for sex, and 0.184 after adjusting for both sex and ordinal age tertile — the finest age granularity the source data allowed. The effect magnitude was preserved in every model, but the confidence intervals marginally crossed zero, and the author explicitly declines to claim covariate-independent statistical significance. This kind of restraint is uncommon in reanalysis studies and reflects the modest number of donors available: with 38 hearts in the discovery cohort, even a robust effect can produce intervals that graze the null.

External validation in the independent SCP1303 cohort strengthened the finding while also defining its boundary. The author-annotated activated fibroblast population, FB-ActFB, was far more abundant in DCM than in normal hearts — a median of 24.11 percent versus 5.16 percent of fibroblasts — with a mean difference of 0.192 and a bootstrap confidence interval of 0.144 to 0.256. All 27 leave-one-donor-out estimates remained positive, and the sex-adjusted coefficient was 0.199 with a p-value of 6.61 × 10⁻⁷. The external state showed concordant MEOX1 and FAP expression, but ACTA2 was not available in the retained external marker summary, and validation relied on the source study’s annotations rather than frozen one-to-one label transfer. The author therefore concludes that the replication supports a shared activation program and abundance shift, not a complete reproduction of the three-marker phenotype or identical cellular identity.

Beyond the state itself, donor-pseudobulk differential expression — in which raw fibroblast counts are summed within each donor before testing — identified several genes elevated in DCM fibroblasts after false-discovery-rate correction. DDAH1 led the list with an adjusted log2 fold change of 2.01, followed by MEOX1 at 2.29 and FAP at 1.89; POSTN, TGFBI, CTGF and COL1A2 also passed correction. Within discovery cluster two, nuclei positive for DDAH1 showed higher extracellular-matrix scores than DDAH1-negative nuclei in paired donor summaries. DDAH1, an enzyme involved in nitric oxide metabolism, has previously been linked to cardiac hypertrophy and remodeling in animal models, which makes it a biologically plausible candidate. The study is emphatic, however, that DDAH1 is a prioritized state-associated candidate, not an established causal regulator, and it was deliberately excluded from the state-defining marker panel to avoid circularity.

The extracellular-matrix evidence itself proved partly method-dependent, a finding the author reports transparently. The donor-pseudobulk ECM score was significantly higher in DCM hearts, with a Mann–Whitney p-value of 0.00975, whereas the cell-derived donor mean showed the same positive direction without reaching significance. The two scoring approaches were nonetheless strongly correlated across donors, with a Spearman correlation of 0.891. Whole-fibroblast pseudobulk differences can reflect both shifts in state composition and expression changes within states, so they cannot by themselves establish cluster-specific regulation. ACTA2, notably, showed a modest overall increase in DCM fibroblasts, reinforcing that the ACTA2-low label describes a relative cluster phenotype rather than a claim that canonical myofibroblasts are absent from the diseased heart.

The study’s limitations are acknowledged candidly: it is a secondary analysis without spatial, protein-level or functional validation; age information was incomplete in both cohorts; reliable etiologic subdivisions of DCM were unavailable; and public-cohort processing differences precluded exact state transfer between datasets. Still, the work delivers something the field genuinely needs — a technically controlled, hypothesis-generating target for prospective experiments. The author proposes that multiplex tissue imaging should test the spatial coexistence of MEOX1, FAP, ACTA2 and DDAH1 in diseased myocardium, while fibroblast perturbation studies should determine whether DDAH1 alters collagen synthesis, matrix organization or state transitions. If those experiments pan out, a fibroblast state first glimpsed in reprocessed public data could point toward new anti-fibrotic strategies for a disease that currently has few options beyond transplantation.

Subject of Research: Identification of a disease-associated MEOX1+FAP+ACTA2-low fibroblast state in dilated cardiomyopathy using cross-cohort single-nucleus RNA sequencing

Article Title: Cross-cohort single-nucleus transcriptomic identification of a MEOX1+FAP+ACTA2-low extracellular matrix-remodeling fibroblast state in dilated cardiomyopathy

Article References: Li, Y. (2026). Cross-cohort single-nucleus transcriptomic identification of a MEOX1+FAP+ACTA2-low extracellular matrix-remodeling fibroblast state in dilated cardiomyopathy. Frontiers in Genetics, 17, Article 1987893. https://doi.org/10.3389/fgene.2026.1987893

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1987893

Keywords: dilated cardiomyopathy, cardiac fibrosis, fibroblasts, single-nucleus RNA sequencing, MEOX1, FAP, ACTA2, DDAH1, extracellular matrix, pseudobulk differential expression, biomarkers, Cross-cohort

Tumor-associated macrophages and microglia collectively constitute one of the largest immune cell populations in glioblastoma, often accounting for up to a third of the total cellular mass of the tumor. Unlike the inflammatory macrophages that would normally sweep into tissue to destroy pathogens or clear damaged cells, macrophages residing inside glioblastomas adopt a profoundly tumor-supportive identity. They secrete growth factors that stimulate tumor cell proliferation, remodel the extracellular matrix in ways that ease invasion, suppress cytotoxic T cell activity, and blunt the effectiveness of immunotherapies that have transformed the treatment of many other cancers. Understanding where these macrophages come from, and what forces shape their immunosuppressive character, has therefore become a central question in neuro-oncology.

The prevailing view has long been that tumor-associated macrophages in the brain arise from two principal sources. The first is the resident microglia, the innate immune cells native to the central nervous system, which become corrupted by tumor-derived signals. The second is circulating monocytes, produced in the bone marrow, which are recruited across the disrupted blood-brain barrier and then differentiate into macrophages within the tumor microenvironment. The new study focuses on this second pathway and asks a deceptively simple question: what cellular intermediaries in the tumor decide that an incoming monocyte should become a macrophage, and what kind of macrophage it becomes?

The answer, the researchers report, involves a population of pericyte-like stromal cells that express fibroblast activation protein, a membrane-bound serine protease that has served for decades as a marker of activated fibroblasts in wound healing and in the desmoplastic stroma of many solid tumors. Pericytes are mural cells that normally wrap around blood vessel endothelial cells, stabilizing vasculature and helping to maintain the blood-brain barrier. In glioblastoma, however, the study indicates that a subset of these pericyte-like cells acquires FAP expression and, with it, a striking new function: the ability to promote the differentiation of monocytes into macrophages with a tumor-associated phenotype.

Technically, the investigators combined single-cell transcriptomic analysis with functional assays to dissect this interaction. Single-cell RNA sequencing allows researchers to profile the gene expression of thousands of individual cells within a tumor, revealing not only the identity of rare cell populations but also the signaling ligands and receptors they deploy. By mapping the communication networks among tumor cells, macrophages, and stromal compartments, the team was able to identify FAP-positive pericyte-like cells as a hub of immunomodulatory signaling. In co-culture experiments, these cells were shown to drive monocytes toward a macrophage fate, biasing the resulting cells toward the immunosuppressive, pro-tumoral polarization that characterizes tumor-associated macrophages in glioblastoma.

The clinical implications of this finding are considerable. Glioblastoma has proven stubbornly resistant to immune checkpoint inhibitors, the antibody therapies that unleash T cells against melanoma, lung cancer, and many other malignancies. One widely cited explanation is that the glioblastoma microenvironment is saturated with immunosuppressive macrophages and microglia that actively paralyze T cells. If FAP-positive pericyte-like cells are among the architects of this immunosuppressive army, then targeting them, or the signals they use to educate monocytes, could represent a way to thin the ranks of tumor-associated macrophages and thereby open a window for T cell-based immunotherapy to function.

Fibroblast activation protein itself is an appealing therapeutic target. It is minimally expressed in healthy adult tissues but abundant in activated stromal cells across multiple cancers, which has already made it the focus of antibody-drug conjugates, small-molecule inhibitors, and radioligand imaging agents in ongoing clinical trials elsewhere in oncology. The demonstration that FAP marks a functionally important stromal population within glioblastoma raises the possibility that strategies developed for pancreatic, breast, and colorectal cancers could be adapted to brain tumors, although the blood-brain barrier and the infiltrative nature of glioblastoma present formidable delivery challenges that any such approach would need to overcome.

Beyond therapy, the study adds an important conceptual layer to the evolving understanding of the glioblastoma microenvironment. Pericytes have traditionally been studied for their roles in vascular biology: they regulate capillary diameter, contribute to blood-brain barrier integrity, and scavenge cellular debris. The idea that a pericyte-derived population can act as an immune educator, converting myeloid precursors into tumor-promoting macrophages, underscores how fluid the functional boundaries are between the vascular, stromal, and immune compartments of a tumor. It also helps explain why glioblastomas are so consistently and comprehensively immunosuppressive: the tumor appears to recruit or reprogram multiple cell types, including structural cells of its own vasculature, into a coordinated anti-immune apparatus.

There remain important questions for future work. The precise molecular signals by which FAP-positive pericyte-like cells induce monocyte differentiation, whether through secreted cytokines such as colony-stimulating factors, direct cell-cell contact, or remodeling of the extracellular matrix, will determine which points in the pathway are most druggable. It will also be essential to establish how these cells are themselves generated, whether they represent a distinct developmental lineage or a pathological reprogramming of ordinary pericytes, and whether their abundance correlates with patient outcomes, treatment resistance, or response to emerging immunotherapies. Longitudinal studies in patient cohorts and validation in additional model systems will be needed to translate the mechanism into prognostic and therapeutic tools.

Nevertheless, the study offers a vivid illustration of how modern single-cell biology is dismantling the old picture of tumors as homogeneous masses of malignant cells. Glioblastoma emerges instead as an ecosystem, one in which tumor cells, immune cells, vascular cells, and stromal cells engage in continuous negotiation, with each population reshaping the others for the tumor’s benefit. Identifying FAP-positive pericyte-like cells as promoters of macrophage differentiation adds a new node to this ecosystem map, and with it, a new set of potential targets. For patients facing a disease with a median survival measured in months despite surgery, radiation, and chemotherapy, every new node represents a new opportunity, and this one connects two of the most immunologically important cell types in the tumor. The hope, shared across the field, is that disrupting this stromal-immune axis could finally give immunotherapy a foothold in one of medicine’s most stubborn cancers.

The distinction between microglia and monocyte-derived macrophages has become increasingly tractable in recent years thanks to advances in single-cell and fate-mapping techniques. Microglia carry a transcriptional signature shaped by their embryonic origin and lifelong residence in the central nervous system, while recruited macrophages retain markers of their bone marrow lineage. Being able to separate these populations reliably matters therapeutically, because the two compartments respond differently to environmental cues and may require different intervention strategies. The identification of a stromal intermediary that actively shapes the monocyte-derived arm adds a layer of specificity to this growing taxonomy.

Pericyte plasticity is itself an area of intense investigation. In models of tissue injury, pericytes can detach from vessels, adopt migratory and secretory behaviors, and participate in scar formation. Similar programs appear to be activated within tumors, where aberrant signaling from malignant cells and from the disrupted vasculature may push pericytes into states that diverge substantially from their physiological roles. The acquisition of fibroblast activation protein expression by pericyte-like cells in glioblastoma fits this broader pattern of stromal remodeling, suggesting that the tumor co-opts a wound-healing-like program for its own purposes.

It is also worth noting that the monocyte-to-macrophage transition is not a single step but a continuum, with intermediate cells that retain plasticity. Signals encountered during recruitment and early differentiation can lock in long-lasting epigenetic programs, meaning that brief exposure to stromal factors may have durable consequences for macrophage behavior. This temporal sensitivity creates potential intervention windows: if the educational signal from FAP-positive cells can be interrupted early, the resulting macrophages might never adopt their tumor-supportive identity.

Finally, the convergence of stromal biology and immunology reflected in this work mirrors a trend across oncology, where cancer-associated fibroblasts and other stromal elements are increasingly recognized as active participants in immune evasion rather than passive scaffolding, reinforcing the case for combination approaches that target both malignant and stromal compartments.

Subject of Research: FAP-positive pericyte-like cells promoting monocyte differentiation into tumor-associated macrophages in glioblastoma

Article Title: FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma

Article References: Houdova Megova, M., Shard, C., Vymolova, B., Ternerova, N., Svablova, T., Buna, T., Straka, D., Vanickova, Z., Krepela, E., Kupcova Skalnikova, H., Kolar, M., Sachova, J., Kubovciak, J., Balaziova, E., Vymola, P., Hrabal, P., Ebert, L. M., Patil, A., Tomas, R., … Sedo, A. (2026). FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01827-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01827-8

Keywords: glioblastoma, tumor-associated macrophages, pericytes, FAP, monocytes, tumor microenvironment, immunosuppression, single-cell sequencing, immunotherapy, neuro-oncology, pericyte-like, cells